Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness

European Respiratory Journal

Volumn 27, Issue 6, 2006, Pages 1144-1151

  Green, Ruth H ^a   Brightling, C E ^a   McKenna, S ^a   Hargadon, B ^a   Neale, N ^a   Parker, D ^a   Ruse, C ^a   Hall, I P ^b   Pavord, I D ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Asthma; Inhaled corticosteroids; Leukotriene antagonists; Long acting 2 agonists; Treatment

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FORMOTEROL; METHACHOLINE; MONTELUKAST; PLACEBO; PREDNISOLONE; SALBUTAMOL; SHORT ACTING DRUG; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; DIAGNOSTIC AGENT; ETHANOLAMINE DERIVATIVE; GLUCOCORTICOID; METHACHOLINE CHLORIDE; QUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MALE; PEAK EXPIRATORY FLOW; PNEUMONIA; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPUTUM; SYMPTOM; BRONCHUS HYPERREACTIVITY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; INHALATION TEST; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; LUNG VOLUME; MIDDLE AGED;

ACETATES; ADMINISTRATION, INHALATION; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BUDESONIDE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EOSINOPHILS; ETHANOLAMINES; GLUCOCORTICOIDS; HUMANS; LEUKOCYTE COUNT; LUNG VOLUME MEASUREMENTS; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; QUINOLINES; SPUTUM;

EID: 33750685972     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00102605     Document Type: Article

References (34)

1. Neville RG, Pearson MG, Richards N, et al. A cost analysis on the pattern of asthma prescribing in the UK. Eur Respir J 1999; 14: 605-609.
2. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411.
3. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-1397.
4. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219-224.
5. Woolcock AJ, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
6. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999; 160: 1862-1868.
7. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-1721.
8. Smith AD, Cowan JO, Brassett KP, Herbison P, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352: 2163-2173.
9. Sent JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159: 1043-1051.
10. Juniper EF, Cockcroft DW, Hargreave FE. Histamine and methacholine inhalaltion tests: tidal breathing method. Laboratory procedure and standardisation. 2nd Edn. Lund, Astra Draco, 1994.
11. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76-83.
12. Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax 1997; 52: 498-501.
13. Brightling CE, Ward R, Woltmann G, et al. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med 2000; 162: 878-882.
14. Hall IP, Wheatley A, Wilding P, Liggett SB. Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995; 345: 1213-1214.
15. Dewar JC, Wilkinson J, Wheatley A, et al. The glutamine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol 1997; 100: 261-265.
16. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353: 2213-2214.
17. Kips JC, Inman MD, Jayaram L, et al. The use of induced sputum in clinical trials. Eur Respir J 2002; 20: Suppl. 37, 47s-50s.
18. Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991; 143: 1317-1321.
19. Jatakanon A, Lim S, Chung KF, Barnes PJ. An inhaled steroid improves markers of airway inflammation in patients with mild asthma. Eur Respir J 1998; 12: 1084-1088.
20. British Thoracic Society; Scottish Intercollegiate Network. British guideline on the management of asthma. Thorax 2003; 58: Suppl. 1, i1-i94.
21. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996-1001.
22. Li X, Ward C, Thien F, et al. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999; 160: 1493-1499.
23. Wallin A, Sandstrom T, Soderberg M, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999; 159: 79-86.
24. Roberts JA, Bradding P, Britten KM, et al. The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999; 14: 275-282.
25. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161: 64-72.
26. Aldridge RE, Hancox RJ, Robin TD, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 2000; 161: 1459-1464.
27. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48: 134-138.
28. Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000; 355: 1675-1679.
29. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353: 364-369.
30. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505-1512.
31. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000; 55: 762-767.
32. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001; 119: 1021-1026.
33. Green RH, Pavord ID. Leukotriene antagonists and symptom control in chronic persistent asthma. Lancet 2001; 357: 1991-1992.
34. Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 1998; 158: 213-219.